Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1995 1
1997 1
1999 1
2001 1
2002 3
2003 3
2004 1
2006 1
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.
Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, Farkas H, Levy R, Baker J, Hardiman Y, Totoritis MC, Relan A, Cicardi M; Study 1310 Investigators. Riedl MA, et al. Among authors: totoritis mc. Ann Allergy Asthma Immunol. 2014 Feb;112(2):163-169.e1. doi: 10.1016/j.anai.2013.12.004. Epub 2014 Jan 7. Ann Allergy Asthma Immunol. 2014. PMID: 24468257 Clinical Trial.
A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds.
Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, Schiller WR, Hansbrough JF, Hickerson WL, Himel HN, Kealey GP, Twomey J, Missavage AE, Solem LD, Davis M, Totoritis M, Gentzkow GD. Purdue GF, et al. Among authors: totoritis m. J Burn Care Rehabil. 1997 Jan-Feb;18(1 Pt 1):52-7. doi: 10.1097/00004630-199701000-00009. J Burn Care Rehabil. 1997. PMID: 9063788 Clinical Trial.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Cohen SB, et al. Among authors: totoritis mc. Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025. Arthritis Rheum. 2006. PMID: 16947627 Free article. Clinical Trial.
16 results